These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 18978489

  • 1. The effects of galantamine on psychopathology in chronic stable schizophrenia.
    Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW.
    Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
    [Abstract] [Full Text] [Related]

  • 2. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW, Lee JG, Lee BJ, Kim YH.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [Abstract] [Full Text] [Related]

  • 3. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP.
    Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
    [Abstract] [Full Text] [Related]

  • 4. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
    Kelly DL, McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley RR, Buchanan RW.
    Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
    [Abstract] [Full Text] [Related]

  • 5. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP, Khan A.
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [Abstract] [Full Text] [Related]

  • 6. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
    Deutsch SI, Schwartz BL, Schooler NR, Brown CH, Rosse RB, Rosse SM.
    Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
    [Abstract] [Full Text] [Related]

  • 7. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [Abstract] [Full Text] [Related]

  • 8. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
    Deutsch SI, Schwartz BL, Schooler NR, Rosse RB, Mastropaolo J, Gaskins B.
    Clin Neuropharmacol; 2008 Oct; 31(1):34-9. PubMed ID: 18303489
    [Abstract] [Full Text] [Related]

  • 9. A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
    Buchanan RW, Kelly DL, Weiner E, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT.
    J Clin Psychopharmacol; 2017 Aug; 37(4):394-400. PubMed ID: 28590362
    [Abstract] [Full Text] [Related]

  • 10. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial.
    Bobo WV, Woodward ND, Sim MY, Jayathilake K, Meltzer HY.
    Schizophr Res; 2011 Aug; 130(1-3):106-13. PubMed ID: 21641776
    [Abstract] [Full Text] [Related]

  • 11. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, Forghani S.
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [Abstract] [Full Text] [Related]

  • 12. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, Xie L, Zhang L, Yang L, Yang S, Yang J, Ruan Y, Zeng Y, Xu X, Zhao J.
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [Abstract] [Full Text] [Related]

  • 13. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 14. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 15. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA.
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R.
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR.
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [Abstract] [Full Text] [Related]

  • 18. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
    Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, Gomez JC.
    Schizophr Res; 2013 Nov; 150(2-3):434-41. PubMed ID: 24035403
    [Abstract] [Full Text] [Related]

  • 19. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM, Yang R, Youakim JM.
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [Abstract] [Full Text] [Related]

  • 20. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
    Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE.
    Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.